In this post, we will be taking a closer look at some of the most popular allergy and immunology-related articles recently published across medical journals.

Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair

  • Immunity
  • February 2025
  • Limited understanding exists regarding the functional heterogeneity of resident versus recruited macrophages in the diseased liver. A population of recruited lipid-associated macrophages (LAMs) has been observed in the diseased liver alongside resident Kupffer cells (KCs). However, the specific roles of these distinct macrophage subsets remain unclear. Through the use of proteogenomics, researchers have identified LAMs in multiple models of liver injury. Interestingly, it was discovered that this phenotype is not exclusive to recruited macrophages, as a subset of resident KCs can also exhibit a LAM-like phenotype in both mouse and human livers. By utilizing genetic mouse models that target these distinct populations, it was determined that both recruited LAMs and resident LAM-like KCs play vital roles in tissue repair.
  • Abstract
  • Full Text

Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer

  • Nature Immunology
  • January 2025
  • The maturation of conventional dendritic cells (cDCs) plays a critical role in maintaining tolerogenic defenses against autoimmunity and in eliciting immune responses to pathogens and cancer. Despite its importance, the subcellular mechanism underlying cDC maturation has remained largely unclear. The research reveals that cDCs undergo maturation by utilizing an internal reservoir of cholesterol, obtained from extracellular cell debris and synthesized de novo, to form lipid nanodomains on their cell surfaces. This process leads to increased expression of maturation markers and enhanced stability of immune receptor signaling. Importantly, this maturation process relies on the transport of cholesterol through Niemann–Pick disease type C1 (NPC1) and is involved in both homeostatic and Toll-like receptor (TLR)-induced maturation.
  • Furthermore, the study identifies the receptor tyrosine kinase AXL as a key regulator of NPC1-dependent lipid nanodomain formation. Deletion of AXL from cDCs results in enhanced maturation, ultimately improving anti-tumor immunity. These findings shed new light on the role of cholesterol mobilization in cDC maturation and underscore AXL as a potential therapeutic target for modulating cDC function.
  • Abstract
  • Full Text

Update on Atopic Dermatitis

  • Journal of Allergy and Clinical Immunology
  • January 2025
  • Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition. This review focuses on the latest advancements in comprehending and managing this debilitating disease. The authors will outline recent discoveries concerning molecular endotypes and clinical phenotypes that define AD, the significance of the skin microbiome, and enhancements in diagnostic techniques. Additionally, they highlight recent scientific breakthroughs in understanding the underlying mechanisms of AD pathogenesis and explore the development and utilization of new targeted treatment strategies that have transformed therapeutic possibilities for individuals affected by this condition.
  • Abstract
  • Full Text

Epigenome-Wide Association Study of Asthma Exacerbations in Europeans

  • Allergy
  • February 2025
  • Asthma exacerbations (AEs) are a significant contributor to the global burden of asthma. While genetic and environmental factors have been linked to AEs, the role of epigenetics in this process has not been fully explored. This study seeks to identify specific DNA methylation (DNAm) markers associated with AEs in individuals of European descent. The findings suggest that DNAm in both whole blood and nasal samples may play a role in the development of AEs in Europeans, potentially capturing a combination of genetic and environmental risk factors.
  • Abstract
  • Full Text

Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains

  • Science Immunology
  • January 2025
  • Trogocytosis is a process in which cells exchange membrane-associated molecules, potentially influencing immune responses. Despite its significance, the regulation of trogocytosis in T cells and its implications remain unclear. The research reveals that T cells can transfer chimeric antigen receptors (CARs) through trogocytosis, equipping recipient T cells with the ability to recognize tumor antigens. This results in the upregulation of proteins linked to cytotoxic responses, leading to the destruction of target cells.
  • Interestingly, the findings indicate that trogocytosis is reliant on cell-cell contact, but the transfer of specific cell membrane proteins does not necessitate a binding partner on the recipient cell's surface. Instead, the likelihood of protein exchange via trogocytosis is influenced by the protein's transmembrane domain. This discovery presents new opportunities for manipulating trogocytosis in CAR-T cells, potentially enhancing their effectiveness in combating tumors.
  • Abstract
  • Full Text

Familial patterns of alopecia areata: A systematic review and meta-analysis

  • Journal of Autoimmunity
  • February 2025
  • Non-infectious aortitis presents with a variety of histological patterns, yet the specific cardiovascular implications remain uncertain. The aim of this study is to assess the mortality rates linked to non-infectious surgical thoracic aortitis.
  • This multicenter study revealed that 31.5% of patients diagnosed with non-infectious surgical thoracic aortitis are projected to succumb within 10 years following their initial surgery. Notably, individuals with the granulomatous/giant cell histological pattern exhibit a heightened mortality risk.
  • Abstract
  • Full Text

Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis

  • Frontiers in Immunology
  • December 2024
  • Telitacicept, a novel biological agent, received approval in China for the treatment of systemic lupus erythematosus (SLE) in 2021. Despite this milestone, the optimal dosing regimen for utilizing Telitacicept in the treatment of SLE remains uncertain. As such, the primary objective of this meta-analysis is to assess the efficacy and safety profile of various doses of Telitacicept in the management of SLE.
  • While the combination of Telitacicept with standard therapy shows promise in improving outcomes for SLE patients, there are notable safety considerations associated with specific dosages of Telitacicept. These findings underscore the need for further research to establish the most effective dosing strategies for the management of SLE.
  • Abstract
  • Full Text

Infant and Toddler Peanut Oral Immunotherapy: Initiation Before Age 2 Increases Ad-Lib Peanut Consumption

  • Journal of Allergy and Clinical Immunology: In Practice
  • February 2025
  • Peanut oral immunotherapy (POIT) shows promising potential for disease modification, yet there is a lack of studies assessing high-dose POIT that allows for unrestricted consumption of peanut products, particularly in children aged 6 months to 4 years. The objective of this study is to present real-world outcomes of high-dose POIT in children aged 6 months to 4 years, focusing on adverse events, the achievement of unrestricted consumption, and the influence of age on these outcomes.
  • The findings of this study indicate that high-dose POIT is well-tolerated in infants and toddlers, and can facilitate the unrestricted inclusion of dietary peanut products, particularly if initiated before the age of two.
  • Abstract
  • Full Text

Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.

  • Current Allergy and Asthma Reports
  • February 2025
  • Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite advancements in treatment, recurrence is a common issue, leading to the investigation of innovative therapies such as monoclonal antibodies targeting the type 2 immune response, specifically dupilumab. This study aims to assess the real-world evidence (RWE) of dupilumab in the treatment of severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.
  • The results support the incorporation of dupilumab into standard treatment protocols for severe CRSwNP, offering a strong alternative that has the potential to decrease the high recurrence rates associated with current management strategies.
  • Abstract
  • Full Text

There you have it - a look at some of the most popular allergy and immunology articles recently released. Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, All Rights Reserved.